'ipo' Tag
-
Europe’s tech IPO market: Where’s Santa?
December 10, 2015Just when it felt like the market for European tech IPOs was opening, the events of the past few weeks have dashed those hopes. Days after Deezer announced the delay of its initial public offering, HelloFresh drew the same conclusion. In France, the only notable IPOs of late were Amundi and ShowroomPrivé. The asset management […]
-
VC Shenanigans, Chapter 1 (of Volume I, Book 1…)
December 3, 2015“Never a dull moment,” one on my favorite co-investors would like to quip. After practicing the business of venture capital for almost a decade and a half now, I’ve witnessed my share of moments that were anything but dull. Someday I’ll write a book, I used to think to myself. Maybe someday. But until then, […]
-
The 3 broken arrows of growth capital in France
June 11, 2013The other day during a stimulating conversation with five of French tech’s movers and shakers, the subject came up about the challenges facing high-potential tech firms in need of growth capital. Setting aside the Yahoo/DailyMotion debacle for a moment (which I fear will carry disastrous long-term consequences for cross-border m&a, one of the three ‘arrows’), […]
-
Euronext’s SME Marketplace
May 7, 2013Last week NYSE Euronext announced the imminent launch of an “SME Marketplace.” Managed by a dedicated subsidiary set up in France, it will have its own brand, operating budget and team. It is hard to understand exactly what this means. Judging from the Euronext press release, the initiative appears to represent more of a hierarchical […]
-
To IPO or not to IPO ?
May 29, 2012Forgive the bastardization of Shakespeare’s Hamlet, because when it comes to French tech IPO’s, one could argue that MacBeth is more appropriate (“Double, double, toil and trouble. Fire burn and cauldron bubble…”). In the last two columns we reviewed the basics of IPO’s and examined some of the challenges that venture-backed companies like Facebook confront […]
-
Going public: It’s complicated
May 22, 2012{Note: this post represents the second installment in a Rude VC series on IPO. The introductory post is here.} Last week in this column we reviewed the basics on an initial public offering, particularly the flavor available in France. Unless you’ve been living in a cave, you would know that since then, Facebook has gone […]
-
The start of a new adventure
May 15, 2012If you’ve been reading the French press recently, you are no doubt aware that this week represents the start of a new adventure… I’m of course referring to the imminent road show for Facebook’s IPO. Already affecting a billion people on the planet, and probably 100% of RudeBaguette readers, Facebook strikes me as the perfect […]
-
From pont neuf to the pinheiros river
June 28, 2011Parabéns to LeadMedia Group for its oversubscribed IPO today ! LeadMedia develops performance-based marketing solutions that enhance online lead generation and customer retention. A company we had first financed in a contrarian move during the dark days of December 2008, LMG has made on a long journey in a short time. Accolades are due to […]
-
Carmat captures investors’ hearts in its successful IPO
July 7, 2010Truffle’s portfolio company Carmat SAS, a French company that’s developing an artificial heart, successfully completed an IPO yesterday above its target. The IPO will allow the company, founded in 2008, to complete pre-clinical trials on the artificial heart and start testing the device on humans. The implantable organ closely resembles a human heart, featuring right […]
-
Another week, another IPO
April 21, 2010Well, it’s been a productive week for Truffle’s life science team. After successful completion of the Neovacs IPO last thursday, today was portfolio company Deinove’s day in the sun. Deinove develops breakthrough technologies which leverage the natural biodiversity and robustness of deinococcus bacteria (existing on Earth for over 3 billion years) to produce bioethanol from […]
-
Truffle Capital’s Neovacs successfully completes its IPO
April 15, 2010Today represents a milestone for Truffle Capital. Our portfolio company Neovacs successfully completed an IPO on NYSE Euronext Paris. This is significant because it represents Truffle’s first IPO in the biotech sector and portends favorably for the public markets. Neovacs is a biotechnology company focused on an active immunotherapy technology platform with applications in autoimmune […]